CD274 and metastatic neoplasm: However, due to the high heterogeneity of PD-L1 expression within both primary tumors and metastases, the ability of IHC detection to accurately evaluate the PD-L1 expression status in real-time and predict treatment response is limited, especially for patients with metastatic diseases [4].